Clinical Evidence: What Research Shows About Peptide Combinations Individual peptides have robust efficacy data: semaglutide shows ~10-15% body weight reduction in GLP-1 agonist trials
Kuyucu S, Mori F, Atanaskovic-Markovic M, Caubet JC, Terreehorst I, Gomes E, et al
Following a thorough analysis of our previous Phase 2b data and trial design, we believe that with the preferred modified release formulation and future trial design optimization, we can advance a competitive oral GLP-1 molecule into registration enabling studies, with the goal of addressing the present and persistent medical needs of people living with obesity. Participants in the study so far have included healthy adults aged 18 years or older and the results thus far have shown a profile that supports once-daily dosing, which is consistent with previous danuglipron studies
Are you comfortable with self-injection
They want to make sure the treatment is safe and effective
Patients may read that as their body building tolerance when the real cause is degradation
